Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 5
2016 4
2017 7
2018 12
2019 17
2020 19
2021 19
2022 18
2023 14
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30719207

101 results

Results by year

Filters applied: . Clear all
Page 1
FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW, Roze JF, Peters EDJ, Sereno F, Brink AGJ, Paijens ST, Nijman HW, van Meurs HS, van Lonkhuijzen LRCW, Piek JMJ, Lok CAR, Monroe GR, van Haaften GW, Zweemer RP. Groeneweg JW, et al. Gynecol Oncol. 2021 Aug;162(2):413-420. doi: 10.1016/j.ygyno.2021.05.027. Epub 2021 Jun 1. Gynecol Oncol. 2021. PMID: 34083028 Free article.
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
Váraljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A, Griewank K, Placke JM, Horn PA, von Neuhoff N, Shannan B, Chauvistré H, Vogel FCE, Horn S, Becker JC, Newton-Bishop J, Stang A, Neyns B, Weide B, Schadendorf D, Roesch A. Váraljai R, et al. JCO Precis Oncol. 2019 Feb 15;3:PO.18.00229. doi: 10.1200/PO.18.00229. eCollection 2020. JCO Precis Oncol. 2019. PMID: 32914028 Free PMC article.
Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D. Chang GA, et al. Mol Oncol. 2016 Jan;10(1):157-65. doi: 10.1016/j.molonc.2015.09.005. Epub 2015 Sep 25. Mol Oncol. 2016. PMID: 26440707 Free PMC article.
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ. Tan L, et al. Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048. Ann Oncol. 2019. PMID: 30838379 Free PMC article.
101 results